14.22
price up icon1.21%   0.17
after-market 시간 외 거래: 14.22
loading
전일 마감가:
$14.05
열려 있는:
$14.04
하루 거래량:
904.82K
Relative Volume:
0.51
시가총액:
$45.08B
수익:
$29.58B
순이익/손실:
$974.15M
주가수익비율:
32.03
EPS:
0.444
순현금흐름:
$3.13B
1주 성능:
+2.67%
1개월 성능:
-1.46%
6개월 성능:
+6.36%
1년 성능:
+1.50%
1일 변동 폭
Value
$14.04
$14.24
1주일 범위
Value
$13.77
$14.24
52주 변동 폭
Value
$12.57
$15.08

다케다약품공업 ADR Stock (TAK) Company Profile

Name
명칭
Takeda Pharmaceutical Co Adr
Name
전화
-
Name
주소
-
Name
직원
49,281
Name
트위터
@takedapharma
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
TAK's Discussions on Twitter

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-03-16 업그레이드 BofA Securities Neutral → Buy
2022-07-19 업그레이드 Cowen Market Perform → Outperform
2021-10-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-04-19 다운그레이드 JP Morgan Overweight → Neutral
2019-11-01 개시 Cowen Market Perform
2019-08-15 다운그레이드 Daiwa Securities Outperform → Neutral
모두보기

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

pulisher
06:00 AM

Prediabetes Market to hit USD 360.6 million by 2032, says Global Market Insights Inc. - GlobeNewswire Inc.

06:00 AM
pulisher
Nov 03, 2024

Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia

Nov 03, 2024
pulisher
Nov 03, 2024

Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa

Nov 03, 2024
pulisher
Nov 02, 2024

Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register

Nov 02, 2024
pulisher
Nov 02, 2024

What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register

Nov 02, 2024
pulisher
Oct 21, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Oct 21, 2024
pulisher
Oct 16, 2024

Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register

Oct 16, 2024
pulisher
Oct 15, 2024

Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily

Oct 15, 2024
pulisher
Oct 11, 2024

Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News

Oct 11, 2024
pulisher
Oct 11, 2024

North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 11, 2024

Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 11, 2024

China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 11, 2024

Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 09, 2024

Checking in on Takeda Pharmaceutical Co ADR (TAK) after recent insiders movement - Knox Daily

Oct 09, 2024
pulisher
Oct 08, 2024

AHH stock rated a Buy by Stifel - Knox Daily

Oct 08, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR

Oct 03, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart

Oct 03, 2024
pulisher
Oct 01, 2024

Ratios in Focus: Analyzing Takeda Pharmaceutical Co ADR (TAK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 01, 2024
pulisher
Sep 26, 2024

Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Brookline Bancorp, Inc. [BRKL] Records 50-Day SMA of $10.01 - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Crescent Energy Co. [CRGY] Records 200-Day SMA of $11.56 - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Tetra Tech, Inc. [TTEK] EVP, CFO makes an insider purchase of 36,830 shares worth 1.72 million. - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

TAK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Sep 26, 2024
pulisher
Sep 16, 2024

Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow

Sep 16, 2024
pulisher
Sep 15, 2024

Ipsen provides update on CONTACT-02 Phase III trial in - GlobeNewswire

Sep 15, 2024
pulisher
Sep 10, 2024

Biotech Soars, And Then Dives, On $5 Billion Opportunity - Investor's Business Daily

Sep 10, 2024
pulisher
Sep 09, 2024

France Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 09, 2024
pulisher
Sep 04, 2024

Middle East & Africa Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 04, 2024
pulisher
Sep 03, 2024

Saudi Arabia Plasma Fractionation Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

The UAE Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

Asia Pacific Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

Japan Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

Kuwait Gout Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research

Sep 03, 2024
pulisher
Aug 28, 2024

Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Aug 28, 2024
pulisher
Aug 23, 2024

Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.

Aug 23, 2024
pulisher
Aug 23, 2024

Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.

Aug 23, 2024
pulisher
Aug 22, 2024

Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - GlobeNewswire Inc.

Aug 22, 2024
pulisher
Aug 21, 2024

Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Aug 21, 2024
pulisher
Aug 19, 2024

Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance

Aug 19, 2024

다케다약품공업 ADR (TAK) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_specialty_generic HLN
$9.77
price up icon 0.10%
$18.77
price up icon 0.70%
$11.61
price up icon 1.40%
$121.53
price up icon 0.83%
drug_manufacturers_specialty_generic ZTS
$175.27
price up icon 0.05%
자본화:     |  볼륨(24시간):